Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeGEV induction therapy before autologous stem cell transplant in relapsed/refractory Hodgkin lymphoma
2010-022169-91Phase 2Completed
- Sponsor
- Humanitas Research Hospital
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, gemcitabine and vinorelbine in Hodgkin lymphoma (HL), sponsored by Humanitas Research Hospital. Primary endpoint: Complete response rate after BeGEV. Started May 2012; status: completed.
02
Drugs
bendamustinegemcitabinevinorelbine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2010-022169-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022169-91.